Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Chronic Heart Failure. According to GlobalData, Phase II drugs for Chronic Heart Failure have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Trientine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trientine hydrochloride overview
trientine hydrochloride is under development for treatment of ischemic heart disease, chronic heart failure, myocardial infarction and left ventricular ejection fraction. It is administered by oral route. The drug candidate is a therapeutic copper binding molecule.
For a complete picture of Trientine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.